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ABSTRACT: Fluorescence anisotropy measurements of
reagents compartmentalized into individual nanoliter droplets
are shown to yield high-resolution binding curves from which
precise dissociation constants (Kd) for protein−peptide
interactions can be inferred. With the current platform, four
titrations can be obtained per minute (based on ∼100 data
points each), with stoichiometries spanning more than 2 orders
of magnitude and requiring only tens of microliters of reagents.
In addition to aﬃnity measurements with puriﬁed components,
Kd values for unpuriﬁed proteins in crude cell lysates can be obtained without prior knowledge of the concentration of the
expressed protein, so that protein puriﬁcation can be avoided. Finally, we show how a competition assay can be set up to perform
focused library screens, so that compound labeling is not required anymore. These data demonstrate the utility of droplet
compartments for the quantitative characterization of biomolecular interactions and establish ﬂuorescence anisotropy imaging as
a quantitative technique in a miniaturized droplet format, which is shown to be as reliable as its macroscopic test tube equivalent.
Protein−ligand interactions interfere with, or promote,essential biological processes such as immune recognition,
signal transduction or enzyme inhibition. Their quantitative
investigation is the basis for systematic and mechanistic
analyses of biological processes and for therapeutic strategies
based on selective molecular intervention. A wide range of
assays exists to assess the strength of binding interactions,
including techniques based on ﬂuorescence probes (e.g.,
lifetime,1 resonance energy transfer,2 and anisotropy3), on
surface immobilization (e.g., surface plasmon resonance,
biolayer interferometry), or on calorimetry (isothermal titration
calorimetry, ITC). Each of these approaches have short-
comings: surface immobilization may aﬀect the properties of
the molecular binding partners (e.g., as a consequence of
conformational changes or molecular crowding);4 ITC requires
large volumes (typically hundreds of microliters) and highly
concentrated reagents, precluding its use for precious and
relatively insoluble samples.5 An attractive choice is ﬂuores-
cence anisotropy (FA) that enables measurements in
homogeneous solution (although it still requires one of the
binding partners to be ﬂuorescently labeled).
Here we introduce a system for the evaluation of binding
interactions by FA in nanoliter water-in-oil droplets, achieving a
∼1000-fold decrease per assay volume (15 nL compared to
typically >13 μL used in a 384-well plate), yet circumventing
some shortcomings of the methods described above: (i) the
assay read-out is independent of signal intensity; (ii) the need
to label only one binding partner reduces the potential for
interference of the label with protein function (e.g., by blocking
binding sites). Furthermore, only a single binding partner has
to be chemically conjugated to a ﬂuorescence reporter, greatly
simplifying the complexity of sample preparation over readouts
where all binding partners have to be labeled (e.g., in assays
exploiting ﬂuorescence resonance energy transfer). Flow
segmentation and microdroplet technology furthermore
decrease assay volumes to the nano- or even femtoliter scale
and speed up sample handling operations; they are therefore
increasingly used for high-throughput studies.6 Recent attempts
to establish ﬂuorescence anisotropy assays in droplets7 involved
the averaging the readout of thousands of droplets to obtain
signal-to-noise ratios suﬃciently precise for deriving quantita-
tive dose−response curves. However, the method still required
the total sample volumes to be in the microliter range. An
attractive alternative approach to save reagents and increase
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throughput would be to obtain a quantitative readout from a
single droplet.8 Here each droplet would correspond to a
speciﬁed ligand/target stoichiometry and the evaluation of the
binding event in each droplet would give rise to a binding
curve. We achieve this by producing a series of single droplets9
with continuously varying reagent stoichiometries in rapid
succession and implementing a highly sensitive readout system
that provides the fraction of bound vs unbound protein. The
resulting dose−response curve is the basis for the quantitative
determination of binding constants.
We explore the potential of single droplet anisotropy
measurements for the study of structure−activity relationships
for protein−protein interactions in nanoliter volumes. Specif-
ically, we address the interactions of the BRC4 peptide, a
reductionist model of the recombination mediator BRCA2,
with mutants of an archaeal surrogate of the recombinase
RAD51.10 The protein interaction pair BRCA2/RAD51 (Figure
1A) is a potential drug target: it is relevant for monitoring
cancer progression, as RAD51 levels are often upregulated in
cancerous cells, conferring resistance to chemotherapy.11
Inhibition of the interaction of BRCA2 and RAD51 has the
potential to sensitize cells to DNA damage, thus potentiating
cancer chemotherapies. To facilitate drug discovery, the two
binding partners have been converted into analogues that
maintain the relevant interactions (i.e., are good functional
mimics of RAD51), but for which it is easier to deconvolute the
binding interactions and thus elucidate structure−activity
relationships: (i) Eight BRC repeats have been identiﬁed in
BRCA2 as interaction partners for RAD51 and a 30−35 amino
acid peptide, corresponding to BRC repeat 4 (BRC4), has been
shown to block RAD51 activity, suggesting a role as a cancer
suppressor.12 (ii) For a fragment-based drug discovery
campaign a monomeric variant, RadA-ct, was derived from an
archaeal homologue (RadA) and humanized, to facilitate
measurement of small molecule binding constants.13 RadA-ct
and its humanized variants (HumRadAs) are much more stable
than RAD51, enabling biophysical analysis of interactions and
development of small molecule inhibitors of this protein−
protein interactions pair. Here, we use a set of previously
described HumRadA mutants with varying aﬃnity for BRC4
peptide (from nonbinding to Kd of 6 nM) as representative
examples to demonstrate that binding can be quantitatively
Figure 1. Schematic view of the quantitative binding assay for protein−protein association in nanoliter droplets. (A) Interaction between BRC4 (in
gray) and RAD51 (of which “HumRadA” proteins are mimics; in red). A ﬂuorescein tag (not shown) was added to the N-terminus of BRC4. (B)
Schematic view of the titration in droplets. The droplets are produced to set up a concentration gradient of the respective HumRadA and are kept in
sequence inside PTFE tubing (I.D. 200 μm), so that the ratio of HumRadA to BRC4fl increases. Spatial encoding preserves the concentration
gradient: initial droplets contain only labeled peptide (BRC4fl), while ﬁnal ones have an excess of the RAD51 analogue, i.e., [HumRadA] ≫
[BRC4fl], and thus, contain an increased proportion of HumRadA-BRC4fl complexes. The size diﬀerence between free and complexed species results
in a change in tumbling rate that can be detected using ﬂuorescence anisotropy. (C) Schematic view of the ﬂuorescence anisotropy detection system
developed for aﬃnity determination. The microdroplet production setup includes one or four wells of a 384-well titerplate (1), containing a
magnetic stirrer (2), and 40 μL of reagent solution (BRC4fl in CHES buﬀer, pH 9.5, 1% w/v BSA), a syringe pump injecting a second component
(3) into the well (HumRadA premixed with BRC4fl in CHES buﬀer, pH 9.5, 1% w/v BSA) and a droplet-forming head made with a pipet tip (4) and
inserted PTFE tubing (5). This assembly produces 10−20 nL droplets and encapsulates a concentration gradient. The PDMS microchannel device
was bonded to a coverslip bottom (7) and droplets in the microchannel were imaged by the microscope with a syringe pump operating in withdrawal
mode that pulls that row of droplets across. The optical setup includes a 488 nm diode laser, a linear polarizer, a multiedge dichroic ﬁlter (DM), a
lens (L1) to focus ﬂuorescence light on a polarization beam splitter, mirrors (M) directing signals with parallel and perpendicular polarizations
toward a lens (L2) to generate spatially separate images on a single CCD camera chip. The microﬂuidic devices featured either one or four parallel
channels. The 20× or 10× objectives of the microscope for the single and the four channel device, respectively, and enabled the imaging of the full
width of the channels. (c.f. inset, right).
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assessed in nanolitre droplets. In addition to the determination
of Kd, our formats for FA measurements in droplets also allow
protein expression levels to be determined, so that cell lysates
rather than puriﬁed components can be used, which simpliﬁes
preparation protocols in practical screening eﬀorts signiﬁcantly.
Finally, we demonstrate that the method has the potential to
screen libraries of competitive ligands eﬀectively.
■ MATERIALS AND METHODS
Optics. Polarization-resolved ﬂuorescence imaging was
performed on a Nikon TE-300 Eclipse microscope with a
custom wideﬁeld detection system. A detailed description of
the applied experimental setup can be found in ref 3. A diode
laser (Cobolt, 488 nm emission wavelength) was coupled into
the microscope through a ﬁxed polarizer for illumination.
Microscopy was performed with a multiedge band-pass dichroic
mirror (MEBP, Semrock Di01-R405/488/561/647), a band-
pass emission ﬁlter (530/43, Semrock), and a 10×, 0.3 NA or
20×, 0.5 NA objective lens. In the detection arm, a rectangular
aperture was placed in the conjugate plane of the specimen to
serve as a ﬁeld stop (FS) to restrict the ﬁeld of view. This was
then relayed onto an Andor iXon DV885 EMCCD camera via a
polarization beamsplitter as shown in Figure 1. The
beamsplitter cube was aligned so that ﬂuorescence polarized
along the parallel and perpendicular directions (with respect to
the illumination axis) were imaged onto separate areas of the
camera. Image data were captured as 16 bit TIF stacks using the
Andor Solis software. A frame rate of 84 Hz, with 10 ms
exposure, was achieved via 8 × 8 binning of the camera pixels. A
Matlab script was written to register the polarization-resolved
images and calculate ﬂuorescence anisotropy on a pixelwise
basis. The mean anisotropy of image regions within the
microdroplet ﬂow cell was then obtained. Anisotropy values for
each pixel i, j were obtained by using the following equation:
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where I∥ and I⊥ represent the emitted ﬂuorescence intensity
measured for the parallel and perpendicular polarizations,
respectively. The variable G represents the ratio of the
detection sensitivities of the detector and is deﬁned for a
specimen with known anisotropy of zero in every pixel (we use
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The G-factor as deﬁned above provides calibration at the
detector level so that each pixel would result in the same
anisotropy value, when calculated according to eq 1 (see SI,
Figure S1). It diﬀers from G-factors used in cuvettes or plate
readers for which a sample of known anisotropy is used to
obtain absolute anisotropy values via measurement using two
laser polarizations oriented at 90° with respect to one
another.14
Fluidics. A droplet sampling system (described by Gielen et
al.15) was used to set up a concentration gradient: 40 μL of
protein in buﬀer were pipetted into a well in a 384-well plate
together with a stir bar (2 × 2 mm, Fisher Scientiﬁc). The
droplet maker was assembled using polytetraﬂuoroethylene
(PTFE) tubing (I.D. 200 μm, O.D. 400 μm) inserted into a cut
gel loading tip (Starlab, 200 μL round, bottom I.D. 360 μm, top
I.D. 5 mm). This tip was then inserted into a polydimethylsi-
loxane (PDMS) slab with a hole of 1 mm in diameter. A total of
10 μL of HFE-7500 + 1% surfactant AZ2C was pipetted into
the oil reservoir (see Figure S2).16 A typical ﬂow withdrawal
rate of 3 μL/min was used to initiate droplet generation. At this
point, a second syringe pump was turned on to continuously
increase the concentration of a second component and produce
droplets of gradually increasing concentration of this second
component. Concentrations for each droplet were derived
using eq S1. At the end of the titrations, droplet formation was
stopped and the sampling head immersed into an oil-containing
well of the plate. The droplet sequence was then transported
through the tubing toward the focal point of the microscope by
using the withdrawal function of the pump again. PDMS
channels were fabricated by soft lithography and bonded to thin
coverslips: they allow droplets to transition from tubing to an
area where they can be imaged (see Figure S3 for designs).
Thus, the chip position did not need to be moved over time,
ensuring consistent spatial registration of measurements for all
the droplets in the sequence.
Preparation of Cell Lysates for Aﬃnity Screens.
HumRadA proteins were produced in 20 mL cultures. After
addition of isopropyl-β-D-thiogalactopyranosid (IPTG; 400
μM), the temperature was reduced from previously 37 °C to
35 °C and cell cultures were incubated for 16 h. Next, the cells
were centrifuged for 5 min at 10 000 rpm, the pellets
resuspended in Luria−Bertani broth (LB) to equal an
OD600 nm of 40. 3.7 × 10
9 cells (assuming an OD600 nm of 1
corresponds to 108 cells/mL) were transferred to a fresh tube,
centrifuged (1 min, 14 000 rpm), the supernatant removed, and
the pellets stored at −80 °C.
After thawing, the cells were lysed by resuspending the pellet
in 200 μL 0.5× BugBuster in 20 mM N-cyclohexyl-2-
aminoethanesulfonic acid (CHES), pH 9.5; containing 100
mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA) and
1% bovine serum albumin (BSA) and the mixture incubated for
15 min at 25 °C. The addition of BSA prevented signiﬁcant
leakage of BRC4fl into the oil phase (see SI, Figure S4). The
cell debris was removed by centrifugation (20 min at 14 000
rpm). The supernatant was diluted with 400 μL of CHES (20
mM, pH 9.5, 100 mM NaCl, 1 mM EDTA, 1% BSA) to reduce
destabilization of droplets by detergents in the BugBuster lysis
agent. The solution was stored at room temperature until used
for the titration. Lysates were always prepared on the day of the
experiment.
MBP-BRC4 Fusion Protein Production. The plasmid
pRSFDuet2-MBP-BRC4 (KanR), encoding a C-terminal fusion
of BRC4 to maltose binding protein (MBP), bearing an N-
terminal His6-tag was generously provided by Dr. L. Pellegrini
and M. Longo, Cambridge University.17 Rosetta2 (DE3) cells
(CmR) were transformed with pRSFDuet2-MBP-BRC4. A 10
mL preculture was prepared and used to inoculate 500 mL of
LB with appropriate antibiotics. After incubation at 37 °C (200
rpm) until an OD600 of 0.6 was reached, the cells were induced
with 400 μM IPTG. After a further 5 h at 37 °C (200 rpm) the
cells were harvested. The pellet was resuspended in 15 mL of
phosphate buﬀered saline (PBS, pH 7.5) and stored at −20 °C.
For protein puriﬁcation, the cells were thawed, 0.5 μL
benzonase added and lysed by sonication. The solution was
centrifuged for 40 min at 6,500 rpm. The supernatant was
loaded on a Ni-NTA (Qiagen) column previously equilibrated
in PBS. The column was washed with 5 bed volumes of 10 mM
imidazole, PBS pH 7.5, and 5 bed volumes of 20 mM imidazole
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in PBS pH 7.5 prior to elution with 2 bed volumes of 250 mM
imidazole in PBS pH 7.5. The protein was concentrated with 30
MWCO spin concentrators (Millipore), while the buﬀer was
exchanged to 20 mM CHES pH 9.5, 100 mM NaCl, 1 mM
EDTA. The puriﬁed protein was stored at 4 °C.
■ RESULTS AND DISCUSSION
Assessment of Binding Aﬃnity by Fluorescence
Anisotropy in a Single Droplet. Concentration gradients
of one binding partner are necessary for recording binding
isotherms. To this end droplets containing varying concen-
trations of puriﬁed HumRadA were generated using a simple
microcapillary technique that produces droplets of deﬁned
concentrations in a spatially encoded sequence. To enable FA
measurements between the binding partners, the smaller
component, BRC4, was labeled at its N-terminal cysteine
with ﬂuorescein after peptide synthesis to give BRC4fl (see SI,
S13.2). While the concentration of HumRadA concentration
increased continuously, the concentration of labeled BRC4 was
kept constant (100 or 20 nM). This led to a continuously
increasing anisotropy value, because the tumbling motion of the
complex is slower than that of the individual binding partners.
The readout of this series of droplets with a varying ratio of
BRC4fl and puriﬁed HumRadA represents a “titration” of the
steady-state binding event (as schematically represented in
Figure 1B).
This droplet sequence representing a concentration gradient
of HumRadA was transported through a microchannel
mounted onto the stage of an inverted microscope. The
microchannel consists of a glass coverslip (thickness 130 μm)
and a bonded rectangular PDMS channel of width 150 μm,
height 220 μm, to which the droplets were delivered via PTFE
tubing inserted into the side of the PDMS block (see
Supporting Information, Figures S2B and S3). The side
insertion enabled the droplets to ﬂow smoothly from the
tubing into the channel without problems caused by ﬂow
instabilities or separation of the conﬁned plugs. This is crucial
to preserve the spatial encoding of sample stoichiometry. The
ﬂuorescence anisotropy signal was read through the glass
portion of the channel chip to maintain the polarization state of
the emitted ﬂuorescence, which would have been impossible via
direct imaging through the PTFE tubing.
Frame-by-frame recordings of parallel/perpendicular ﬂuo-
rescence intensities enabled the extraction of the total intensity
and anisotropy maps for a rectangular region of interest (ROI),
as deﬁned in Figure 2 (Videos S1 and S2, SI).
Determination of Kd Values for Protein−Protein
Interactions. The process of quantifying data from FA
measurements from individual droplets and mapping them to
HumRadA concentration is shown in Figure 3. HumRadA
samples were added to BRC4fl, while keeping the BRC4fl
concentration constant. To ensure constant ﬂuorescence
intensity, a HumRadA solution containing BRC4fl was slowly
titrated to a BRC4fl solution and droplets were generated
sequentially (see Figure 3).
First, the start of each titration was identiﬁed by the ﬁrst
droplet for which ﬂuorescence anisotropy was at least 0.5 mP
above that of droplets containing BRC4fl only (Figure 3A).
Concentrations for each droplet could be calculated analytically
from the known ﬂow parameters (initial volume Vi, ﬂow rates
of infusion and withdrawal, qin and qout, respectively), and the
time the droplet was generated, using eq S1. For the ﬂow
conditions used here, minor mis-assignments of droplets and
concentrations lead to negligible errors in calculated Kd. In
practice we estimate the assignment to be precise to within 1 s,
corresponding to a potential shift in Kd, on the order of 10%.
Next, the average droplet-by-droplet anisotropy values were
extracted (Figure 3B).
Anisotropy values for the ligand alone were found to be
accurately quantiﬁed down to 5 nM, below which the signal got
Figure 2. Anisotropy values are extracted frame-by-frame from intensity maps in steps A−C. The subscripts “sc” and “4c” refer to the single channel
or four parallel channel conﬁgurations, respectively (with the latter quadrupling the throughput). (A) Raw intensity images for parallel and
perpendicular ﬂuorescence channels obtained from a rectangular ﬁeld of view within a single droplet containing 100 nM BRC4fl. (B) Anisotropy
maps calculated from the raw data shown in (A). (C) Anisotropy histograms of a single frame used for data quantiﬁcation. For a setup with four
channels, ROIs were deﬁned for each parallel channel. The transformation from intensity maps into anisotropy values was achieved using a Matlab
code (https://github.com/quantitativeimaging/icetropy).
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too weak (Figure S5). We also found that there was a
signiﬁcant eﬀect of focal position within the droplet volume on
the determination of anisotropy values (as seen in Figure S6 of
the Supporting Information), which we ascribed to the
presence of ligand at the interface oil/water with a high
anisotropy contribution. However, the diﬀerence in the
measured anisotropies between the fully bound and fully
unbound scenarios was largely independent of focus and varied
by less than 5% for all conditions stated here, as seen in Figure
S7. Thus, the measurement of the diﬀerence provides a robust
readout so that initial anisotropy values with fully unbound
ligands can be subtracted from all readings. Experiments
yielded comparable results, even when microﬂuidic devices
were removed and replaced or between diﬀerent ﬂow-chip
designs. The standard deviation of the mean anisotropy for
each frame was found to be around 12 mP, whereas the
Figure 3. Addition of HumRadA leads to increased anisotropy. (A) Frame-by-frame data extraction of both total intensity (blue) and mean
anisotropy (green) for a chosen ROI (as depicted in Figure 2A). The experiment is conducted with increasing [HumRadA] and constant [BRC4fl].
(B) Anisotropy and intensity data corresponding to the dashed rectangle in (A). This trace corresponds to six individual droplets passing through the
ﬁeld of view. Periods of high brightness in the region of interest correspond to the presence of a droplet. The dashed regions in (B) indicate periods
when the region of interest is ﬁlled by a droplet, during which it is typically possible to obtain 70 frames of image data once the data are trimmed to
exclude frames where the region of interest is only partially ﬁlled by the droplet. The anisotropy of the droplet and the measurement uncertainty can
be estimated as the mean and standard deviation of these 70 values. (C) Anisotropy values plotted as a function of theoretical concentration of
protein in each droplet calculated from the time when the droplet picture was taken (frame number). Vertical error bars correspond to the standard
deviation of the mean anisotropy for each droplet. The black trace is the best ﬁt obtained using eq 3. (D) Four dose−response curves for
HumRadA18 obtained in parallel with the four-channel device.
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standard deviation of the mean anisotropy for the accumulated
70 frames corresponding to a single droplet was around 8 mP
(Figure S8). Thus, there is no beneﬁt to be derived from using
larger droplets or using multiple droplets containing the same
concentration conditions to improve data quality.
Kd values were subsequently extracted using the following
equation, in which binding equilibrium is assumed.18
= + + +
− + + −
× −
A A K
K
A A
([HumRadA ]) ([BRC4] [HumRadA ] )
(([BRC4] [HumRadA ] ) 4[BRC4][HumRadA ])
2[BRC4]
x x
x x
F d
d
2
C F
(3)
Here AC and AF are the anisotropy values for fully bound (AC),
and fully unbound (AF) states, respectively, and [HumRadAx]
refers to the concentration of the respective HumRadA protein
variants.
The ﬁt for HumRadA18 at 5 nM BRC4fl gave a Kd of 49.3 ±
0.5 nM (Figure 3C). In an analogous HumRadA18 titration in
the parallelized setup featuring four channel device the Kd
values were extracted as 52.0 ± 2.0, 55.9 ± 2.9, 49.1 ± 1.4, and
56.3 ± 3.0 nM, respectively, for a 100 nM concentration for
BRC4fl. All measurements were within the error of the ﬁt,
suggesting minimal variation between diﬀerent series of droplet
concentrations and diﬀerent positions in one device.
Titrations of HumRadA Variants. Next, three representa-
tive HumRadA proteins with aﬃnities between 4 and 670 nM
were titrated to demonstrate the ability of the method to rank
variants. These HumRadA mutants were designed to be
increasingly similar to human RAD51 and their aﬃnity for
BRC4 varies accordingly. Mutants HumRadA14 and HumRa-
dA16 lack two polar residues, which interact directly with the
BRC4 peptide. An A266R mutation in HumRadA16 introduces
a salt-bridge with BRC4 residue E1548, while the acidic side
chain of residue D198 introduced in HumRadA18 reinstates a
polar interaction with BRC4 residue S1528; both of these
mutations are found in HumRadA20 and HumRadA22,
explaining why the highest BRC4 aﬃnity is expected with
these proteins.
To rank the aﬃnity of these proteins, we expressed, puriﬁed
and titrated them against pure BRC4fl. To this end, the
concentration of BRC4fl was kept constant at either 100 or 5
nM for laser powers of 5 and 50 mW, respectively.
Figure 4 summarizes the dose−response curves obtained. As
expected, at 100 nM BRC4fl, the dose−responses for
HumRadA18 and HumRadA20 were well resolved, whereas
HumRadA14 exhibited a signiﬁcantly higher Kd. On the other
hand, reducing BRC4fl concentration and using higher laser
power (50 mW) permitted a clear diﬀerentiation between
HumRadA18 and HumRadA20. The aﬃnity of HumRadA14
was not determined at 5 nM BRC4fl because its Kd is too far
from this concentration of ligand and would result in a shallow
titration for the same range of protein concentrations with poor
prospects for useful data ﬁtting. Table 1 summarizes the Kd
values obtained using a standard 96-well plate format in
comparison to the data obtained by measurements in droplets.
The Kd values derived from droplet experiments are
consistently around 3-fold higher than those obtained from
titer plate assays, which may indicate residual leakage of BRC4fl
as well as aﬃnity of BRC4fl for the oil−water interface. Other
oil/surfactant combinations might result in better retention
properties for BRC4fl.20 Figure S4 shows that ﬂuorescence
intensity does not plateau at 1% BSA, suggesting that we have
not reached full retention yet and further improvements are
possible. However, the ranking is entirely consistent between
the droplet and the plate assay. Moreover, it has been reported
Figure 4. Titration of BRC4fl with diﬀerent HumRadA variants. (A) Duplicate titrations of HumRadA 14 (red), HumRadA18 (blue), and
HumRadA20 (green) at constant 100 nM BRC4fl. Kd values extracted from the ﬁts to eq 1 indicate 15.9 ± 0.5, 34.5 ± 1.9, and 2015 ± 102 nM for
HumRadA20, HumRadA18, and HumRadA14, respectively. (B) Titrations of HumRadA18 (blue) and HumRadA20 (green) at constant 5 nM
BRC4fl. Kd values were found to be 11.0 ± 0.2 and 32.1 ± 0.4 nM for HumRadA20 and HumRadA18, respectively.
Table 1. Comparison of Dissociation Constants Kd Obtained from Fluorescence Anisotropy Measurements in Droplets
(Droplets of 10−20 nL) and in a Titerplate (Well Volume: 100μL)a
Kd (nM) droplet
c (100 nM BRC4fl)
HumRadA variants 96-well plateb (10 nM BRC4fl) repeat 1 repeat 2 avg dropletc (5 nM BRC4fl)
HumRadA14 670 ± 12 2130 ± 100 1901 ± 22 2015 ± 102 not determined
HumRadA18 10.7 ± 0.4 32.9 ± 1.3 36.2 ± 1.4 34.5 ± 1.9 32.1 ± 0.4
HumRadA20 3.9 ± 0.2 14.6 ± 0.5 17.2 ± 0.2 15.9 ± 0.5 11.0 ± 0.2
aConditions in titerplate measurements: 100 μL of 100 nM BRC4fl at varying HumRadA concentrations; [CHES] = 20 mM, pH 9.5, 100 mM NaCl,
1 mM EDTA. Conditions in each droplet: 20 nL at 100 nM BRC4fl at varying HumRadA concentrations; 20 mM, pH 9.5, 100 mM NaCl, 1 mM
EDTA, 1% BSA. All measurements were performed at room temperature. Standard deviations come from the ﬁtting algorithm based on a single
titration. bSee ref 19. cSee curves in Figure 4a,b.
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that variations in Kd values using diﬀerent techniques can result
in up to 1 order of magnitude discrepancy.21
Simultaneous Determination of Protein Expression
and Aﬃnity by Screening of Cell Lysates. In order to
simplify ﬂuorescence anisotropy assays in droplets further, we
designed an experimental setup in which aﬃnity determination
of HumRadA variants could be carried out without the need of
purifying one of the two protein binding partners. We ﬁrst
veriﬁed the assumption that cell lysate components did not
interfere with BRC4fl by varying the amount of cell lysate not
expressing any HumRadA and measuring the FA increase
(Figure S9). The FA signal was found not to change over the
course of the titration (up to 45% lysate) within sensitivity
limits for 100 nM BRC4fl and increase by 2.5 mP at 30% lysate
at 20 nM, indicating little nonspeciﬁc interactions between
BRC4 and other cellular components (accounting for less than
10% of the dynamic of the assay; ∼34 mP). Instead, lysates of
E. coli cells expressing HumRadA were directly assayed. In
contrast to the puriﬁed protein sample with a known protein
concentration, two titrations have to be performed with two
distinct concentrations of BRC4fl (Figure 5A). In order to
probe the potential of lysate screenings to yield high quality Kd
values, all ﬁve HumRadA variants, HumRadA14, 16, 18, 20, and
22, were expressed and their cell lysates analyzed. A global
ﬁtting algorithm can then be used to infer two unique linear
correlations between stock protein concentration and Kd and
the intersection of these two correlations gives a unique
solution as shown in Figure 5B. Table 2 summarizes the Kd and
protein concentrations found for all HumRadA variants (for
primary data, see SI, Figure S10).
An immediate advantage of this setup was that much less
HumRadA sample was necessary to perform these measure-
ments. Because only 40 μL cell lysate was needed to obtain a
full titration curve, a cell culture of 20 mL provided suﬃcient
material to measure Kd as well as the protein expression yield
(c.f. Table 2).
The quality of estimates of the Kd and HumRadA
concentration was found to depend on the two chosen
BRC4fl concentrations that in turn determine how well the
intersection is deﬁned. Thus, linear correlations with very
similar slopes lead to larger uncertainty. Therefore, the BRC4fl
concentration should diﬀer suﬃciently (in our case, 5-fold),
and, ideally, one concentration should be above and one below
Kd. In addition, expression levels should be ideally much higher
than Kd to reach saturation of binding conditions in order to
get a good linear relationship between dissociation constant
and protein concentration, as was indeed case for
[HumRadA22]lysate = 577 nM compared to the measured Kd
of 10 nM.
Despite the huge range of expression levels spanning a 30-
fold concentration range, we obtained Kd values similar to those
measured previously.19 However, as is the case for
HumRadA14, HumRadA16, and HumRadA18, low expression
or high Kd lead to higher statistical errors (below 25%). While
HumRadA20 and 22 reverse their rank order in FA droplet
assays compared to plate assays, this is not due to insuﬃcient
data quality: a low Kd and high protein expression lead to <6%
error in Kd and concentration for these HumRadAs. These
results can be rationalized by an error that is larger than the
statistical error and which precludes the diﬀerentiation of
binders as similar as HumRadA20 and 22 (∼2-fold Kd
diﬀerence). Taken together, these observations suggest that
FA measurements in droplets can produce data that match
experiments on the microliter scale and also conﬁrm the
previous achievements of aﬃnity enhancement of HumRadA
variants by humanization of RadA.19 Errors made are larger
when measuring aﬃnities with Kd values substantially below or
above ligand concentration BRC4fl, because this technique does
not yield enough data points to ﬁt the nonlinear data
adequately.
Screening for BRC4 Competitors. BRC4 derivatives have
potential as modulators of up-regulated RAD51 expression and
an eﬃcient method to obtain structure−activity relationships
Figure 5. Screening of cell lysates to derive dissociation constant Kd and protein concentration. (A) Two HumRadA22 cell lysates were titrated into
100 (blue) and 20 nM (red) BRC4fl. (B) Each curve ﬁt results in a linear relationship between dissociation constant (Kd) and protein concentration
([HumRadA22]lysate). The intersection of the lines gives the only Kd and protein concentration value that solves both line equations derived from the
titrations at 100 and 20 nM, respectively. (C) Example ﬁts taken along the two correlation lines of (B). Only the intersect point denoted I gives an
accurate ﬁt for both curves ([HumRadA22]lysate = 653 ± 15 nM, Kd = 11 ± 0.5 nM).
Table 2. Dissociation Constants and Protein Concentrations
Obtained from FA Measurements of Cell Lysates (SI, Figure
S8)a
HumRadA Kd
b (nM) Kd
c (nM) [HumRadA]d (nM)
HumRadA14 670 ± 12 910 ± 130 780 ± 110
HumRadA16 294 ± 6 250 ± 7 273 ± 8
HumRadA18 10.3 ± 0.4 17 ± 5 35 ± 4
HumRadA20 3.9 ± 0.2 15 ± 2 831 ± 30
HumRadA22 6.2 ± 0.3 11 ± 0.5 653 ± 15
aConditions: CHES 20 mM, pH 9.5, 100 mM NaCl, 1 mM EDTA, 1%
BSA, T = 24 °C. Two titrations were performed at 100 and 20 nM
ligand BRC4fl concentration, respectively, so that both Kd and
expression levels were derived. bTaken from ref 19. Kd values
determined with puriﬁed HumRadAs in microtiter plates. cMeasured
by FA analysis in lysate screens, as described in this work.
dConcentration in lysate and determined by the lysate screen
described here. Standard deviations for droplets measurements were
obtained from the global ﬁt from one single experiment.
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for RAD51 binders would thus be highly interesting. However,
producing a large number of ﬂuorescent peptides is expensive
and time-consuming. Therefore, we established a competition
assay, which evaluates the replacement of preincubated BRC4fl
bound to HumRadA protein by unlabeled peptide. Competi-
tion by the fusion protein MBP-BRC4 (MBP) was tested, as
shown schematically in Figure 6A. Although MBP-BRC4 does
not have a higher aﬃnity than BRC4fl for HumRadA it will
outcompete BRC4fl at high concentrations. The MBP-BRC4
concentration was gradually increased across a sequence of
droplets, while keeping the total concentration of BRC4fl and
HumRadA18 constant.
The curves were plotted using eq S2 to transform anisotropy
readings into percentages of binding (Figure 6B and SI, S11).
We used the framework of the complete competitive binding
model as described in reference 18. Out-competing BRC4fl at
40 nM for HumRadA18 at 60 nM with MBP-BRC4 gives a Kd
of 110 ± 3 nM ﬁtted to eq S3 (SI, S12).
This shows that the assay is able to quantitatively screen
HumRadA18 binders with a singly labeled ligand. Even though
the starting HumRadA18-BRC4fl bound fraction is below 50%
to ensure eﬃcient replacement of BRC4fl by BRC4-MBP, the
high sensitivity of the platform is nonetheless capable of a
reasonable quantiﬁcation of interactions.
■ SUMMARY
We demonstrate that ﬂuorescence anisotropy can be performed
with quantitative precision in nanoliter droplets, where each
droplet encodes for a diﬀerent protein/ligand stoichiometry.
Each droplet can be analyzed individually and in rapid sequence
to establish precise dose−response curves with small sample
volumes (30−1000 droplets per titration) on very short time
scales (minutes). This is in contrast to continuous droplet ﬂow
approaches which rely on massive signal averaging over many
monoclonal droplets. Previously, it appeared to be necessary to
average signals over very large number of droplets (>10 000)7
to obtain suﬃcient signal with FA and for the determination of
a Kd, which meant that, despite the small volume of one
droplet, such experiments consumed microliter total volumes
(350 pL × 10 000 = 3.5 μL). Furthermore, to provide a
suﬃcient number of data points for construction of a titration
curve with continuous droplet ﬂow approaches requires labor
intensive reloading of syringes, frequent adjustment periods to
equilibrate ﬂow conditions and to ensure monodisperse droplet
formation. Finally, adjusting mixing conditions through actively
controlled variations of ﬂow rates permits only a limited
dynamic range to be obtained, typically less than 2 orders of
magnitude: the droplet-on-demand systems in turn are able
span several orders of magnitude.6c,22 Apart from device
designs with classical T- or ﬂow focusing junctions,23 the
miniaturization of liquid-phase assays using FA below microliter
volumes has been demonstrated in nanoliter microwells.24 To
obtain binding curves containing 10 data points took 15 min in
48 × 48 nanoliter chamber arrays using a commercial
microﬂuidic device.24 The approach was costly and required
complex ﬂuidics connections, while still relying on manual
pipetting for each concentration point screened.
By contrast, in our experimental design one set of conditions
is represented by a single droplet, so that a 200-fold reduction
in reagent volume (3.5 μL/15 nL) is possible to obtain data
points of comparable quality in a titration curve. Table 3
Figure 6. Competition assay performed in nanoliter droplets. (A) Schematic representation of the competition assay in nanoliter plugs. Both the
receptor HumRadA18 and the labeled ligand BRC4fl were kept at constant concentration during the whole titration while the MBP-BRC4
concentration is increasing from 0 to 7 μM. (B) Competition of MBP-BRC4 construct with BRC4fl against HumRadA18. Binding curves were
normalized to % of bound HumRadA18-BRC4fl. Two identical repeat titrations are overlaid. The well contained initially 40 μL of 40 nM BRC4fl and
60 nM HumRadA18 in CHES buﬀer pH 9.5, 1% BSA (w/v). The injection of puriﬁed MBP-BRC4 was done at a ﬂow rate of 2.5 μL/min (for 1 min)
followed by 17.5 μL/min (for 1 min). Vertical error bars correspond to the standard deviation of the mean anisotropy for each droplet.
Table 3. Performance Comparison of Diﬀerent Formats for Anisotropy Measurementsa
format
No. of measurements for
each sample composition
volume consumed for one
sample composition (nL)
total sample
volume (nL)
typical number of sample
compositions per curve
total volume per
titration (μL) ref
96-well plates 1 100 000b 100 000 12e 1200
384-well plates 1 13 000b 13 000 24e 312
continuous analysis of
multiple droplets
10 000 0.35c 3500d 10 35 7
single droplet on-
demand analysis
1 15c 15 100 1.5 this work
aConventional microtiter plate screen, continuous multidroplet analysis, and the analysis of single nanoliter droplets presented in this work. The
term “sample composition” corresponds, for example, to one concentration in a binding curve or a Michaelis-Menten plot. bMicrowell volume.
cDroplet volume. dVolume of 10000 droplets. eNumber of wells in one row of a plate.
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contrasts the quantitative descriptors of this design with
experiments in microtiter plates and with continuous analysis
of ﬂowing droplets. Our approach achieves excellent sensitivity
and data quality through careful design of the ﬂuidic device and
calibration of the optical anisotropy imaging platform, which
incorporates an image-based registration and G-factor calibra-
tion.3 The precise determinations of dose response curves
require minimal or no requirement for manual operator
intervention. More data points can be generated per run
(>100) and the overall run time required to perform a full
titration experiment is very short (<1 min). The setup is
relatively straightforward and can be multiplexed, as we have
demonstrated with a simple four-channel device that
quadruples the throughput. The feature of sampling droplets
from an open well brings ﬂexibility in setting up on-demand
concentration gradients,6c,22a for instance, through use of
sequential injection patterns.
Using the current implementation of the droplet sampler, the
overall volume consumed for one high-resolution titration was
40 μL of HumRadA variant (at a concentration ideally 10 times
above Kd in order to reach signal saturation), spiked with 100
nM BRC4fl and 40 μL of pure BRC4fl (at 100 nM). Each
droplet had a volume of 15 nL (compared to 13 μL needed for
a standard 384-well titer plate format, ∼1000-fold volume
reduction). Such small volumes enabled the screening of cell
lysates produced in 20 mL cultures (instead of 1.3 L culture for
the equivalent titration in a 96-well screen), further reducing
screening cost and eﬀort. We showed that extracting the two
key parameters, Kd and level of protein expression, was possible
via acquisition of just two high-resolution titrations. In addition,
the FA signals from the lysates were found to be highly speciﬁc
to HumRadA-BRC4fl interactions, potentially paving the way
for diagnostic applications from more complex sample matrices
(e.g., bodily ﬂuids).25 The ability to determine precise FA
signals in single droplets also provides the basis for coupling
detection with library selections in formats in which droplets
cocompartmentalize genotype and phenotype.26 Anisotropy
detection would expand the range of assays that can be used for
library selections in protein engineering by directed evolution27
or metagenomic screening,8c to enable not only assays that lead
to production of ﬂuorophores (e.g., as leaving groups8b), but
also, assays that instead detect size changes by ﬂuorescence
anisotropy (e.g., for enzymatic breakdown of macromolecular
targets by proteases of glycosidases).
Ultimately the sensitivity of the technique is limited by the
optical setup (detector quality, laser power), but we could
readily detect low nM binders at high laser powers (50 mW)
and 100 ms integration time. The precision of anisotropy
measurement (and, hence, the precision with which binding
fractions can be estimated) is limited by the ﬂuorescence signal
from the reagents, which stray background light levels (e.g.,
light scattered from the oil droplet interfaces). In practice, this
can be achieved down to nM concentration.
Additionally, we showed that day-to-day comparisons of FA
binding curves were possible via G-factor calibration and simple
subtraction of the “base” anisotropy values of a calibration
sample (the freely tumbling labeled ligand), without the need
for further normalizations, which have potential to introduce
bias.
We established this approach as a mature technology that
was able to rank the known aﬃnities of HumRadAs, humanized
forms of RadA, and established a method for quickly
characterizing further variants using cell lysates. We also
showed that an MBP-BRC construct can be used to set up
libraries of BRC mutants, potentially able to out-compete the
already tight-binding BRC4; a better binder would be highly
valuable for benchmarking of drug studies as well as going
further toward the understanding of BRCA2-RAD51 inter-
actions.
The aﬃnity determination between a small ligand and
proteins is key to drawing structure−activity relationships. The
use of ﬂuorescence anisotropy is highly attractive for biological
experiments, because only a single labeling step required. As we
shown here, it also enables liquid-phase assays in complex
mixtures such as cell lysates, quantifying dissociation constants
from nanoliter droplets with uncomplicated microﬂuidics and
integration with a standard ﬂuorescence microscope. The
technique can readily detect low nM binders. Parallelization of
the assays enables the acquisition of 50 titrations per day with
hundreds of data points each across over 2 orders of magnitude.
The number of potential targets for which FA is routinely used
is vast, ranging from the detection of interactions of small
binding motifs such as SH2 domains28 or STATs29 to the
screening of small molecule drug,30 with particular advantages
conferred by the method if the samples are contained in
complex solutions.31 More broadly, the rapid advances in high-
throughput biology32 and its applications, for example, in
directed evolution,27 single cell biology, and diagnostics33
suggest a prominent future role of quantitative single-droplet
analysis based on FA.
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